20934-51-4

Usage

Uses

Used in Organic Synthesis:
2,3-Quinoxalinedione,1,4-dihydro-1-methyl-(6CI,7CI,9CI) is used as a building block in organic synthesis for the production of various chemicals. Its unique structure allows it to be a versatile component in the creation of new compounds with potential applications in various industries.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, 2,3-Quinoxalinedione,1,4-dihydro-1-methyl-(6CI,7CI,9CI) is used as an intermediate for the synthesis of various drugs. Its potential biological activity makes it a promising candidate for the development of new medications and therapeutic agents.
Used in Research and Development:
2,3-Quinoxalinedione,1,4-dihydro-1-methyl-(6CI,7CI,9CI) is also of interest for further research and development due to its potential biological activity. Scientists and researchers are exploring its properties and applications to better understand its potential uses and benefits in various fields.

InChI:InChI=1/C9H8N2O2/c1-11-7-5-3-2-4-6(7)10-8(12)9(11)13/h2-5H,1H3,(H,10,12)

Upstream product

• 144-62-7 oxalic acid 
• 4760-34-3 N-methyl-1,2-phenylenediamine 
• 95-92-1 oxalic acid diethyl ester 
• 80310-02-7 1-carboxymethyl-1,2,3,4-tetrahydroquinoxaline-3-one 
• 79-37-8 oxalyl dichloride 
• 4755-77-5 Ethyl oxalyl chloride 
• 95-54-5 1,2-diamino-benzene 
• 612-28-2 2-nitro-N-methylaniline 
• 4732-69-8 Chloro-oxo-acetic acid 
• 6479-18-1 1-methyl-2(1H)-quinoxalinone 
• 872-50-4 1-methyl-pyrrolidin-2-one 
• 1196-57-2 quinoxalin-2⁽¹⁾-one 

Downstream Products

• 58175-07-8 1,4-dimethylquinoxaline-2,3(1H,4H)-dione 
• 2213-63-0 2,3-dichloroquinoxaline 
• 857089-92-0 3-(4-iodo-phenylamino)-1-methyl-1H-quinoxalin-2-one 
• 869199-22-4 3-(3-amino-phenylamino)-1-methyl-1H-quinoxalin-2-one 
• 857089-85-1 3-(4-amino-phenylamino)-1-methyl-1H-quinoxalin-2-one 
• 869199-05-3 4-[methyl-(4-methyl-3-oxo-3,4-dihydro-quinoxalin-2-yl)-amino]-benzoic acid methyl ester 
• 857089-75-9 4-(4-methyl-3-oxo-3,4-dihydro-quinoxalin-2-ylamino)-benzoic acid methyl ester 
• 80708-30-1 1-Oxo-5-methyl-1H,4H(1,2,4)triazolo(4,3-a)quinoxalin-4-one 
• 55686-67-4 1-methyl-3-piperazin-1-yl-1H-quinoxalin-2-one 
• 860503-54-4 1-methyl-3-phenoxy-1H-quinoxalin-2-one 

Relevant academic research and scientific papers

Organic photoredox catalyzed C-H silylation of quinoxalinones or electron-deficient heteroarenes under ambient air conditions

Direct C-H silylation of quinoxalinones was achieved by the combination of organic photoredox catalysis and hydrogen atom transfer (HAT) under ambient air conditions. Transition metal- and external oxidant-free conditions were the major features of this protocol. A series of silylated quinoxalinones with broad functional groups had been synthesized in moderate to high yields. This methodology was also applicable for the C-H silylation of some electron-deficient heteroarenes.

Direct C3-H carbamoylation of quinoxalin-2(1H)-ones with isocyanides enabled by selectfluor II under mild conditions

A F reagent-mediated direct C-H carbamoylation of quinoxalin-2(1H)-ones has been developed. Under room temperature, a variety of isocyanides are employed to couple well with quinoxalin-2(1H)-ones affording 42 examples including 30 new compounds. This metal-free mild strategy tolerates a wide range of functional groups and shows environmental friendliness and practicality.

K2S2O8-catalyzed highly regioselective amidoalkylation of diverse N-heteroaromatics in water under visible light irradiation

A K2S2O8-catalyzed versatile C(sp2)-C(sp3) bond formation with N-heteroaromatics and γ-lactams/amides was developed. Quinoxalin-2(1H)-one, quinoline, isoquinoline, phthalazine, and benzothiazole reacted with γ-lactams/amides to give the corresponding C(sp2)-H amidoalkylation products in moderate to good yields with high regioselectivity. This visible-light-induced photocatalyst-free reaction was conducted in H2O at ambient temperature, which comply with the principles of "green chemistry". The new K2S2O8 catalytic mechanism was investigated with control experiments.

Green synthesis method of N-substituted-1,4-dihydro-2,3-quinoxalinedione compound

The invention discloses a green synthesis method of an N-substituted-1,4-dihydro-2,3-quinoxalinedione compound. The green synthesis method comprises the following steps: reacting ammonium persulfate with an N-substituted quinoxaline-2(1H)-one derivative in an aqueous solution of DL-alpha-tocopherol methoxy polyethylene glycol succinic acid water to generate the N-substituted-1,4-dihydro-2,3-quinoxalinedione compound; and after the reaction is finished, extracting a reaction product by using ethyl acetate, and performing vacuum drying to obtain the high-purity target product. The aqueous solution of the DL-alpha-tocopherol methoxy polyethylene glycol succinic acid can be recycled at least five times or more. The method is good in product selectivity, high in yield, simple in separation process, low in raw material cost, friendly to environment and beneficial for industrial production and application.

Metal-Free C3 Hydroxylation of Quinoxalin-2(1H)-ones in Water

A practical protocol for the preparation of quinoxaline-2,3(1H,4H)-diones through direct C(sp2)?H hydroxylation of quinoxalin-2(1H)-ones in recyclable DL-α-Tocopherol methoxypolyethylene glycol succinate solution (2 wt% in water) (TPGS-750-M/H

Synthesis and evaluation of 3-anilino-quinoxalinones as glycogen phosphorylase inhibitors

A series of 3-anilino-quinoxalinones has been identified as a new class of glycogen phosphorylase inhibitors. The lead compound 1 was identified through high throughput screening as well as through pharmacophore-based electronic screening. Modifications were made to the scaffold of 1 to produce novel analogues, some of which are 25 times more potent than the lead compound.

Quinoxalinones

The invention features quinoxalinones, pharmaceutical compositions containing them and methods of using them to treat, for example, diabetes.

Glycine receptor antagonists and the use thereof

Methods of treating or preventing neuronal loss associated with stroke, ischemia, CNS trauma, hypoglycemia and surgery, as well as treating neurodegenerative diseases including Alzheimer's disease, amyotrophic lateral sclerosis, Huntington's disease and Down's syndrome, treating or preventing the adverse consequences of the hyperactivity of the excitatory amino acids, as well as treating anxiety, chronic pain, convulsions, inducing anesthesia and treating psychosis are disclosed by administering to an animal in need of such treatment a compound having high affinity for the glycine binding site, lacking PCP side effects and which crosses the blood brain barrier of the animal. Also disclosed are novel 1,4-dihydroquinoxaline-2,3-diones, and pharmaceutical compositions thereof. Also disclosed are highly soluble ammonium salts of 1,4-dihydroquinoxaline-2,3-diones.

Tricyclic heterocyclic compounds as psychopharmaceuticals

New heterocyclic compounds having the general formula STR1 wherein STR2 CO2 R' or CONR'R", wherein R' and R" independently are C1-6 -alkyl, C3-7 -cycloalkyl or C1-6 -alkoxymethyl; --A-- is --C(=O)--NR'"--, --NR'"--C(=O)--, or STR3 wherein R'" is C1-6 -alkyl; X is C or N; and R4 is hydrogen, halogen, CN, C1-6 -alkyl, C1-6 -alkynyl, trimethylsilyl-C1-6 -alkynyl, aryloxy which may be substituted with halogen, aralkoxy, C3-7 -cycloalkoxy which may be substituted with one or more C1-6 -alkyl groups, or NR""R'"", wherein R"" and R'"" independently are C1-6 -alkoxy or together with the nitrogen atom form a 3-7 membered heterocyclic ring. The compounds are useful in psychopharmaceutical preparations as anticonvulsants, anxiolytics, hypnotics, and nootropics.

A FACILE SYNTHESIS OF NOVEL TRICYCLIC COMPOUNDS, TETRAZOLOQUINOXALINES AND 1,2,4-TRIAZOLOQUINOXALINES

Novel 5-methyltetrazoloquinoxalin-4-ones (5) and 5-methyl-1,2,4-triazoloquinoxalin-4-ones (7) could be synthesized from 1-methyl-3-chloroquinoxalin-2-ones (3) and 1-methyl-3-hydrazinoquinoxalin-2-ones (6), respectively.Further extensive study was carried out to synthesize 4- or 7- substituted and 4,7-disubstituted tetrazoloquinoxalines (10) and 1,2,4-triazoloquinoxalines (12).